FY2025 EPS Forecast for MiNK Therapeutics Lifted by Analyst

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Research analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of MiNK Therapeutics in a report released on Monday, November 17th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($3.07) per share for the year, up from their previous forecast of ($3.36). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($0.92) EPS, FY2026 earnings at ($3.61) EPS, FY2027 earnings at ($3.85) EPS, FY2028 earnings at ($1.52) EPS and FY2029 earnings at $0.49 EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.21.

INKT has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut shares of MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd. Finally, Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Stock Down 5.8%

Shares of INKT opened at $11.31 on Wednesday. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00. The stock has a fifty day simple moving average of $14.17 and a two-hundred day simple moving average of $12.94. The company has a market capitalization of $53.04 million, a PE ratio of -3.73 and a beta of 0.33.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.